DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA) today announces antihypertensive results with its
lead monoclonal antibody DM-204. Consistent and significant blood pressure
lowering results are observed with DM-204 in all animals and the lower blood
pressure occurred for the duration of the study performed.


In a preclinical study conducted by Physiogenix Inc. (Madison, WI), DiaMedica's
DM-204 has been shown to significantly and durably lower systolic blood pressure
in all animals by an average of 15 mm Hg (p less than 0.05) over the duration of
the study. These findings have important implications for commercial prospects
of DM-204 for treating hypertension (high blood pressure). DM-204 blocks the
activity of glycogen synthase kinase 3 beta (GSK3B), a key cell signaling enzyme
linked to several diseases including diabetes and certain cancers. 


Hypertension affects nearly one third of adult Americans and is a leading risk
factor for early cardiovascular disease and stroke. Hypertensive patients are
adequately controlling their blood pressure in only 20% of cases with currently
available medicines. Multiple antihypertensive medications are often required to
treat patients with high blood pressure. Moreover, approximately 70% of Type 2
diabetes patients suffer from high blood pressure. As a result, an
anti-hypertensive therapy that simultaneously improves the diabetic condition is
expected to have greatly enhanced commercial prospects. 


"If the significant lowering of systolic blood pressure observed in the
pre-clinical study is emulated clinically, then DM-204 has the potential to
replace the current standard of care for treating hypertension patients. The
current standard of care typically consists of a daily administration of two or
more drugs compared with our single compound, which could potentially be
administered as infrequently as once a month," stated Rick Pauls, President and
CEO of DiaMedica. "Results of the present study further demonstrate the
exceptional potential of DM-204 that is also being tested for diabetes and other
indications".


About Hypertension 

Hypertension (high blood pressure) is a chronic medical condition in which blood
pressure is elevated to 140 mm Hg or greater systolic or 90 mm Hg or greater
diastolic blood pressure. Approximately 75 million Americans and close to one
billion people worldwide are affected by hypertension. Adults of all ages and
backgrounds can develop hypertension including 70% of patients with Type 2
diabetes. According to The American Heart Association estimates, the direct and
indirect expenses associated with hypertension cost the health care system more
than $73 billion in 2009.


About DiaMedica Inc. 

DiaMedica is a biopharmaceutical company focused on developing novel therapeutic
products that could dramatically improve the lives of people with Type 1
diabetes, Type 2 diabetes and other large unmet diseases. DiaMedica's lead drug
DM-199 has been shown to significantly improve glucose metabolism and protect
and proliferate beta cells.


The Company is listed on the Toronto Stock Exchange Venture under the trading
symbol "DMA". 


For additional information please visit the Companies website: www.diamedica.com.

Caution Regarding Forward-Looking Information 

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, the "forward-looking statements"). These
forward-looking statements relate to, among other things, DiaMedica's
objectives, goals, targets, strategies, intentions, plans, beliefs, estimates
and outlook, and can, in some cases, be identified by the use of words such as
"believe," "anticipate," "expect," "intend," "plan," "will," "may" and other
similar expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or circumstances are
forward-looking statements. Specifically, this press release contains
forward-looking statements regarding matters such as, but not limited to, the
anticipated use of proceeds from the Offering, management's assessment of
DiaMedica's future plans, information with respect to the advancement of
DiaMedica's research and development programs, and DiaMedica's other estimates
and expectations. These statements reflect management's current beliefs and are
based on information currently available to management. Certain material factors
or assumptions are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in such
statements. Important factors that could cause actual results to differ
materially from these expectations include, among other things: uncertainties
and risks related to our research and development programs, the availability of
additional financing, risks and uncertainties relating to the anticipated use of
proceeds, changes in debt and equity markets, uncertainties related to clinical
trials and product development, rapid technological change, uncertainties
related to forecasts, competition, potential product liability, additional
financing requirements and access to capital, unproven markets, the cost and
supply of raw materials, management of growth, effects of insurers' willingness
to pay for products, risks related to regulatory matters and risks related to
intellectual property matters.


Additional information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found in the body
of this news release, as well as under the heading "Risk Factors" contained in
DiaMedica's 2009 annual information form. DiaMedica cautions that the foregoing
list of important factors that may affect future results is not exhaustive. When
relying on DiaMedica's forward-looking statements to make decisions with respect
to DiaMedica, investors and others should carefully consider the foregoing
factors and other uncertainties and potential events. Such forward-looking
statements are based on a number of estimates and assumptions, which may prove
to be incorrect, including, but not limited to, assumptions regarding the
availability of additional financing for research and development companies, and
general business and economic conditions. These risks and uncertainties should
be considered carefully and investors and others should not place undue reliance
on the forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management believes to be
reasonable assumptions, DiaMedica cannot provide assurance that actual results
will be consistent with these forward-looking statements. DiaMedica undertakes
no obligation to update or revise any forward-looking statement. Additional risk
factors, factors which could cause actual results to differ materially from
expectations, and assumptions relating specifically to our acquisition of
Sanomune may be found in our press releases dated February 18, 2010 and April
20, 2010.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024